ADS032
/ Adiso Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 27, 2023
A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases.
(PubMed, Clin Transl Immunology)
- "Critically, ADS032 protected mice from lethal influenza A virus challenge, displayed increased survival and reduced pulmonary inflammation. ADS032 is the first described dual inflammasome inhibitor and a potential therapeutic to treat both NLRP1- and NLRP3-associated inflammatory diseases and also constitutes a novel tool that allows examination of the role of NLRP1 in human disease."
Journal • Infectious Disease • Inflammation • Influenza • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL18 • IL1B • NLRP1 • NLRP3 • TNFA
1 to 1
Of
1
Go to page
1